Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market Portraiture
2.1.1. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2016 (US$ Mn)
2.1.2. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market Share, by Geography, 2016 (Value %)
Chapter 3. Myelodysplastic Syndrome (MDS) Treatment Drugs: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016
Chapter 4. Pipeline Analysis of Myelodysplastic Syndrome (MDS) Treatment Drugs
4.1. Overview
4.2. Pipeline Analysis of Phase 3 Drugs
4.3. Tabular Presentation of Phase 1 and Phase 2 Drugs
Chapter 5. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. Attractive Investment Proposition, by Drug Class, 2016
5.3. Hypomethylating Agents
5.3.1. Azacitidine
5.3.2. Decitabine
5.4. Immunomodulatory Drugs
5.4.1. Lenalidomide
5.5. Growth Factors
5.5.1. Epoetin Alfa
5.5.2. Darbepoetin Alfa
5.5.3. Filgrastim
5.6. Others
5.6.1. Cytarabine
5.6.2. Daunorubicin
5.6.3. Idarubicin
5.6.4. Topotecan
5.6.5. Fludarabine
Chapter 6. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2015 – 2025
6.2.1. North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.2.2. North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2015 – 2025
6.3.1. Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.3.2. Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.4.2.1. China
6.4.2.2. Japan
6.4.2.3. Rest of APAC
6.5. Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2015 – 2025
6.5.1. Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2015 – 2025
6.6.1. MEA Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.6.2. MEA Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Region, 2015 – 2025 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA
Chapter 7. Company Profiles
7.1. Bayer AG
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Drug Class Portfolio
7.1.4. Key Developments
7.2. Celator Pharmaceuticals (Jazz Pharmaceuticals plc.)
7.3. Celgene Corporation
7.4. Cell Therapeutics, Inc.
7.5. Daiichi Sankyo Company, Ltd.
7.6. Incyte Corporation
7.7. Janssen Biotech, Inc.
7.8. MedImmune, LLC (AstraZeneca)
7.9. Millennium Pharmaceuticals (Takeda Pharmaceutical)
7.10. Novartis AG
7.11. Onconova Therapeutics, Inc.
7.12. Pfizer, Inc.
7.13. Taiho Pharmaceutical (Otsuka Holdings)
7.14. Other Notable Players
List of Figures
FIG. 1 Myelodysplastic Syndrome (MDS) Treatment Drugs: Market Segmentation
FIG. 2 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2016 (US$ Mn)
FIG. 3 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2016
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Azacitidine Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Decitabine Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Lenalidomide Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Epoetin Alfa Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Darbepoetin Alfa Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Filgrastim Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Cytarabine Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Daunorubicin Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global Idarubicin Market, 2015 – 2025 (US$ Mn)
FIG. 15 Global Topotecan Market, 2015 – 2025 (US$ Mn)
FIG. 16 Global Fludarabine Market, 2015 – 2025 (US$ Mn)
FIG. 17 U.S. Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 18 Canada Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 19 U.K. Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 20 Germany Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 21 Rest of Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 22 Japan Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 23 China Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 24 Rest of Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 25 Brazil Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 26 Mexico Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 27 Rest of Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 28 GCC Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 29 Rest of Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
List of Tables
TABLE 1 Global Myelodysplastic Syndrome Market Portraiture
TABLE 2 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 3 North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 4 North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)